{"pmid":32338827,"title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19.","text":["ISTH interim guidance on recognition and management of coagulopathy in COVID-19.","J Thromb Haemost","Thachil, Jecko","Tang, Ning","Gando, Satoshi","Falanga, Anna","Cattaneo, Marco","Levi, Marcel","Clark, Cary","Iba, Toshiaki","32338827"],"journal":"J Thromb Haemost","authors":["Thachil, Jecko","Tang, Ning","Gando, Satoshi","Falanga, Anna","Cattaneo, Marco","Levi, Marcel","Clark, Cary","Iba, Toshiaki"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32338827","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jth.14810","topics":["Prevention"],"weight":1,"_version_":1665264685484605440,"score":8.574329,"similar":[{"pmid":32302442,"title":"RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19.","text":["RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19.","The unrelenting acceleration of COVID-19 infections due to SARS-CoV-2 is unquestionably the greatest medical challenge of our professional careers. The Scientific and Standardisation Committee (SSC) on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) is to be commended for the rapid publication of guidance for clinicians worldwide to assist in management of the coagulopathy widely reported to be associated with severe COVID-19 infection. However, we would like to offer constructive feedback as to how the SSC's interim guidance1 might be improved.","J Thromb Haemost","Akima, Satoshi","McLintock, Claire","Hunt, Beverley J","32302442"],"abstract":["The unrelenting acceleration of COVID-19 infections due to SARS-CoV-2 is unquestionably the greatest medical challenge of our professional careers. The Scientific and Standardisation Committee (SSC) on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) is to be commended for the rapid publication of guidance for clinicians worldwide to assist in management of the coagulopathy widely reported to be associated with severe COVID-19 infection. However, we would like to offer constructive feedback as to how the SSC's interim guidance1 might be improved."],"journal":"J Thromb Haemost","authors":["Akima, Satoshi","McLintock, Claire","Hunt, Beverley J"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302442","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14853","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664635401228255232,"score":202.63234},{"pmid":32302462,"title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","text":["ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.","We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure.","J Thromb Haemost","Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E","32302462"],"abstract":["We read with interest the International Society on Thrombosis and Hemostasis interim guidance on recognition and management of coagulopathy in COVID-19 (1). We applaud this group's efforts in releasing a timely article on the pandemic impacting all regions of the globe. While we agree that this interim guidance addresses important considerations for monitoring the disease process, we believe that the proposed treatment strategy of prophylactic low molecular weight heparin (LMWH) to treat severe COVID-19 coagulopathy is an unconvincing strategy. Patients that are critically ill with COVID-19 have hallmark signs of disseminated intravascular coagulation (DIC)(2), and as noted in the ISTH interim guidance and our own clinical practice, thrombosis is the overwhelming phenotype with rare bleeding complications. We address this concern with the existing data on the severe hypercoagulable state of COVID-19 victims and advocate for consideration of systemic anticoagulation with unfractionated heparin to prevent life threatening micro- and macrovascular thrombosis to mitigate their associated consequences, up to and including progression of respiratory and organ failure."],"journal":"J Thromb Haemost","authors":["Barrett, Christopher D","Moore, Hunter B","Yaffe, Michael B","Moore, Ernest E"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302462","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14860","keywords":["acute respiratory distress syndrome (ards)","anticoagulation","covid-19","disseminated intravascular coagulation","international society on thrombosis and haemostasis (isth)"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["ISTH"],"e_drugs":["Heparin","Heparin, Low-Molecular-Weight"],"_version_":1664635401358278656,"score":197.74223},{"pmid":32160345,"title":"ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals.","text":["ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals.","Ultrasound Obstet Gynecol","Poon, L C","Yang, H","Lee, J C S","Copel, J A","Leung, T Y","Zhang, Y","Chen, D","Prefumo, F","32160345"],"journal":"Ultrasound Obstet Gynecol","authors":["Poon, L C","Yang, H","Lee, J C S","Copel, J A","Leung, T Y","Zhang, Y","Chen, D","Prefumo, F"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32160345","week":"202011|Mar 09 - Mar 15","doi":"10.1002/uog.22013","source":"PubMed","topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1664640874799169537,"score":52.532856},{"pmid":32302459,"title":"COVID19 and acute coagulopathy in pregnancy.","text":["COVID19 and acute coagulopathy in pregnancy.","We present a putative link between maternal COVID19 infection in the peripartum period and rapid maternal deterioration with early organ dysfunction and coagulopathy. The current pandemic with SARS-CoV-2 has already resulted in high numbers of critically ill patients and deaths in the non-pregnant population, mainly due to respiratory failure. During viral outbreaks, pregnancy poses a uniquely increased risk to women due to changes to immune function, alongside physiological adaptive alterations, such as increased oxygen consumption and edema of the respiratory tract. The laboratory derangements may be reminiscent of HELLP syndrome, and thus knowledge of the COVID19 relationship is paramount for appropriate diagnosis and management. In addition to routine measurements of D-dimers, prothrombin time, and platelet count in all patients presenting with COVID19 as per ISTH guidance, monitoring of APTT and fibrinogen levels should be considered in pregnancy, as highlighted in this report. These investigations in SARS-CoV-2-positive pregnant women are vital, as their derangement may signal a more severe COVID19 infection, and may warrant pre-emptive admission and consideration of delivery to achieve maternal stabilization.","J Thromb Haemost","Vlachodimitropoulou Koumoutsea, Evangelia","Vivanti, Alexandre J","Shehata, Nadine","Benachi, Alexandra","Le Gouez, Agnes","Desconclois, Celine","Whittle, Wendy","Snelgrove, John","Malinowski, Kinga Ann","32302459"],"abstract":["We present a putative link between maternal COVID19 infection in the peripartum period and rapid maternal deterioration with early organ dysfunction and coagulopathy. The current pandemic with SARS-CoV-2 has already resulted in high numbers of critically ill patients and deaths in the non-pregnant population, mainly due to respiratory failure. During viral outbreaks, pregnancy poses a uniquely increased risk to women due to changes to immune function, alongside physiological adaptive alterations, such as increased oxygen consumption and edema of the respiratory tract. The laboratory derangements may be reminiscent of HELLP syndrome, and thus knowledge of the COVID19 relationship is paramount for appropriate diagnosis and management. In addition to routine measurements of D-dimers, prothrombin time, and platelet count in all patients presenting with COVID19 as per ISTH guidance, monitoring of APTT and fibrinogen levels should be considered in pregnancy, as highlighted in this report. These investigations in SARS-CoV-2-positive pregnant women are vital, as their derangement may signal a more severe COVID19 infection, and may warrant pre-emptive admission and consideration of delivery to achieve maternal stabilization."],"journal":"J Thromb Haemost","authors":["Vlachodimitropoulou Koumoutsea, Evangelia","Vivanti, Alexandre J","Shehata, Nadine","Benachi, Alexandra","Le Gouez, Agnes","Desconclois, Celine","Whittle, Wendy","Snelgrove, John","Malinowski, Kinga Ann"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302459","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14856","source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1664635401414901760,"score":50.52397},{"pmid":32330308,"title":"COVID-19 Coagulopathy in Caucasian patients.","text":["COVID-19 Coagulopathy in Caucasian patients.","Although the pathophysiology underlying severe COVID-19 remains poorly understood, accumulating data suggest that a lung-centric coagulopathy may play an important role. Elevated D-dimer levels which correlated inversely with overall survival were recently reported in Chinese cohort studies. Critically however, ethnicity has major effects on thrombotic risk, with a 3-4 fold lower risk in Chinese compared to Caucasians and a significantly higher risk in African-Americans. In this study, we investigated COVID-19 coagulopathy in Caucasian patients. Our findings confirm that severe COVID-19 infection is associated with a significant coagulopathy that correlates with disease severity. Importantly however, Caucasian COVID-19 patients on LMWH thrombo-prophylaxis rarely develop overt DIC. In rare COVID-19 cases where DIC does develop, it tends to be restricted to late stage disease. Collectively, these data suggest that the diffuse bilateral pulmonary inflammation observed in COVID-19 is associated with a novel pulmonary-specific vasculopathy which we have termed pulmonary intravascular coagulopathy (PIC) as distinct to DIC. Given that thrombotic risk is significantly impacted by race, coupled with the accumulating evidence that coagulopathy is important in COVID-19 pathogenesis, our findings raise the intriguing possibility that pulmonary vasculopathy may contribute to the unexplained differences that are beginning to emerge highlighting racial susceptibility to COVID-19 mortality.","Br J Haematol","Fogarty, Helen","Townsend, Liam","Ni Cheallaigh, Cliona","Bergin, Colm","Martin-Loeches, Ignacio","Browne, Paul","Bacon, Christopher L","Gaule, Richard","Gillett, Alexander","Byrne, Mary","Ryan, Kevin","O'Connell, Niamh","O'Sullivan, Jamie M","Conlan, Niall","O' Donnell, James S","32330308"],"abstract":["Although the pathophysiology underlying severe COVID-19 remains poorly understood, accumulating data suggest that a lung-centric coagulopathy may play an important role. Elevated D-dimer levels which correlated inversely with overall survival were recently reported in Chinese cohort studies. Critically however, ethnicity has major effects on thrombotic risk, with a 3-4 fold lower risk in Chinese compared to Caucasians and a significantly higher risk in African-Americans. In this study, we investigated COVID-19 coagulopathy in Caucasian patients. Our findings confirm that severe COVID-19 infection is associated with a significant coagulopathy that correlates with disease severity. Importantly however, Caucasian COVID-19 patients on LMWH thrombo-prophylaxis rarely develop overt DIC. In rare COVID-19 cases where DIC does develop, it tends to be restricted to late stage disease. Collectively, these data suggest that the diffuse bilateral pulmonary inflammation observed in COVID-19 is associated with a novel pulmonary-specific vasculopathy which we have termed pulmonary intravascular coagulopathy (PIC) as distinct to DIC. Given that thrombotic risk is significantly impacted by race, coupled with the accumulating evidence that coagulopathy is important in COVID-19 pathogenesis, our findings raise the intriguing possibility that pulmonary vasculopathy may contribute to the unexplained differences that are beginning to emerge highlighting racial susceptibility to COVID-19 mortality."],"journal":"Br J Haematol","authors":["Fogarty, Helen","Townsend, Liam","Ni Cheallaigh, Cliona","Bergin, Colm","Martin-Loeches, Ignacio","Browne, Paul","Bacon, Christopher L","Gaule, Richard","Gillett, Alexander","Byrne, Mary","Ryan, Kevin","O'Connell, Niamh","O'Sullivan, Jamie M","Conlan, Niall","O' Donnell, James S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330308","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bjh.16749","keywords":["covid-19","coagulation parameter","d-dimer","novel coronavirus pneumonia"],"source":"PubMed","topics":["Mechanism"],"weight":1,"locations":["Chinese","Chinese","Caucasians","African-Americans","Caucasian","Caucasian","Caucasian"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664996914903384065,"score":50.52397}]}